LONDON ¿ Alizyme plc, of Cambridge, said it received permission to conduct a United Kingdom Phase II trial of renzapride (ATL 1251) for the treatment of constipation-predominant irritable bowel syndrome (IBS). The trial of the compound, which was in-licensed from SmithKline Beecham, of London, will begin in June.

On completion of Phase II, SKB has the right to take back the compound, a 5-HT4 receptor agonist/5-HT3 receptor antagonist, in return for repayments, milestones and royalties to Alizyme. In IBS, peristalsis is disrupted. 5-HT receptors influence intestinal motility. ¿ Nuala Moran